← All trials
NCT02412319
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shineway Pharmaceutical Co.,LtdLead sponsor
- Ningxia Medical UniversityOverall official - principal investigator
- Linyi People's HospitalOverall official - principal investigator
- Liaocheng People's HospitalOverall official - principal investigator
- Qingdao Infectious Diseases HospitalOverall official - principal investigator
- The Third Hospital of Qinhuangdao CityOverall official - principal investigator
- Weifang People's HospitalOverall official - principal investigator
- Tai'an Central HospitalOverall official - principal investigator
- The Third People's Hospital of TaiyuanOverall official - principal investigator
- Luohe Central HospitalOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Qingdao UniversityOverall official - principal investigator
- Peking UniversityStudy chair
- People's Liberation Army of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.